Analytical Data
-
Gene name
CFX
- Application
-
Alternative Names
CFX；sms；DNA repair Protein RadA
-
Species
E.coli
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P24554
-
Expression Region
1-460aa
-
AA Sequence
MAKAPKRAFVCNECGADYPRWQGQCSACHAWNTITEVRLAASPMVARNERLSGYAGSAGVAKVQKLSDISLEELPRFSTGFKEFDRVLGGGVVPGSAILIGGNPGAGKSTLLLQTLCKLAQQMKTLYVTGEESLQQVAMRAHRLGLPTDNLNMLSETSIEQICLIAEEEQPKLMVIDSIQVMHMADVQSSPGSVAQVRETAAYLTRFAKTRGVAIVMVGHVTKDGSLAGPKVLEHCIDCSVLLDGDADSRFRTLRSHKNRFGAVNELGVFAMTEQGLREVSNPSAIFLSRGDEVTSGSSVMVVWEGTRPLLVEIQALVDHSMMANPRRVAVGLEQNRLAILLAVLHRHGGLQMADQDVFVNVVGGVKVTETSADLALLLAMVSSLRDRPLPQDLVVFGEVGLAGEIRPVPSGQERISEAAKHGFRRAIVPAANVPKKAPEGMQIFGVKKLSDALSVFDDL
-
Molecular Weight
49.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CFX, or Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, plays a crucial role in maintaining the balance of salt and water on epithelial surfaces in various organs, particularly the lungs and pancreas. Mutations in the CFTR gene can lead to cystic fibrosis, a genetic disorder characterized by thick mucus buildup, leading to severe respiratory and digestive issues. Research into CFX recombinant proteins aims to better understand the structure and function of CFTR, facilitate the development of therapies to restore its function, and explore innovative approaches for treating cystic fibrosis. Recombinant proteins can be engineered to study specific aspects of CFTR and to test potential drugs that might correct defective CFTR proteins or enhance their function. As scientists delve into the complexities of CFTR's mechanisms and interactions within the cellular environment, this research not only sheds light on the pathophysiology of cystic fibrosis but also paves the way for novel therapeutic strategies, potentially improving the quality of life for patients affected by this condition. The ongoing studies seek to evaluate the efficacy of small molecule correctors and potentiators that target various CFTR mutations, thus broadening the therapeutic horizon for cystic fibrosis.
